

Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:52:09 ON 17 SEP 2003

=> file caplus uspatful jepio europatful medline biosis embase cancerlit
'JEPPIO' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):japio

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:52:58 ON 17 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 13:52:58 ON 17 SEP 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 13:52:58 ON 17 SEP 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'EUROPATFULL' ENTERED AT 13:52:58 ON 17 SEP 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'MEDLINE' ENTERED AT 13:52:58 ON 17 SEP 2003

FILE 'BIOSIS' ENTERED AT 13:52:58 ON 17 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 13:52:58 ON 17 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 13:52:58 ON 17 SEP 2003

=> s implant? and biodegrad? and prostat?
L1 3581 IMPLANT? AND BIODEGRAD? AND PROSTAT?

=> s l1 and steroid?

L2 1105 L1 AND STEROID?

=> s 12 and PSA

L3 105 L2 AND PSA

=> s 13 and (estrogen? or progester? or corticosteroid?)

L4 57 L3 AND (ESTROGEN? OR PROGESTER? OR CORTICOSTEROID?)

=> s 14 and ((anti androgen?) or flutamide or bicalutamide or nilutamide)

L5 21 L4 AND ((ANTI ANDROGEN?) OR FLUTAMIDE OR BICALUTAMIDE OR NILUTAMIDE)

=> s 15 and (micropart? or microcapsule? or microencapsul? or nanocapsule? or nanosphere? or nanopart? or microsphere?)

L6 20 L5 AND (MICROPART? OR MICROCAPSULE? OR MICROENCAPSUL? OR NANOCAPSULE? OR NANOSPHERE? OR NANOPART? OR MICROSPHERE?)

=> s 16 and (saline or anesthetic or ethanol)

L7 17 L6 AND (SALINE OR ANESTHETIC OR ETHANOL)

=> s 17 and (retropubic? or (transperennial?) or (transrectal?))

L8 8 L7 AND (RETROPUBIC? OR (TRANSPERENNIAL?) OR (TRANSRECTAL?))

=> s 18 and (subcutaneous? or intramuscular?)

L9 8 L8 AND (SUBCUTANEOUS? OR INTRAMUSCULAR?)

=> d 19 1-8 ibib abs

L9 ANSWER 1 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:213299 USPATFULL

TITLE: Prostatic hormonal implants
treatment of prostate cancer

INVENTOR(S): Sahadevan, Velayudhan, Beckley, WV, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147936	A1	20030807
APPLICATION INFO.:	US 2002-72416	A1	20020207 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Dr. V. Sahadevan, Dag Hammarskjold Cancer Treatment Center, 155 Dry Hill Road, Beckley, WV, 25801		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	4229		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk **prostate** cancers by **prostatic implants** of androgen suppressive drugs formulated as fused with a lipid carrier or encapsulated in **microcapsules** or in Silastic capsules is provided. Such **prostatic implants** renders a constant slow-release of their contents to the **prostate** for extended periods by **biodegradation** and diffusion. It facilitates higher **prostatic** and lower systemic concentrations of androgen suppressive hormones. Because of their high **prostatic** and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal **implant** treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of **PSA** and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage **prostate** cancer is reserved for

those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage **prostate** cancer significantly. Androgen suppressive hormonal **implants** to the **prostate** before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized **prostate** cancer as compared to the more complex and toxic higher dose radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2002:102479 USPATFULL
TITLE: Methods for treating sex hormone-dependent conditions with Lhrh antagonists
INVENTOR(S): Garnick, Marc B., Brookline, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6384017	B1	20020507
APPLICATION INFO.:	US 2000-697409		20001026 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-438174, filed on 11 Nov 1999, now patented, Pat. No. US 6180609 Continuation of Ser. No. US 1998-108664, filed on 1 Jul 1998, now patented, Pat. No. US 6153586 Continuation of Ser. No. US 1995-573109, filed on 15 Dec 1995, now patented, Pat. No. US 5780435, issued on 14 Jul 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	825		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex **steroid** biosynthesis to the subject in combination with the LHRH-R antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2001:48027 USPATFULL
TITLE: Methods for treating LHRH associated disorders with LHRH antagonists
INVENTOR(S): Garnick, Marc B., Brookline, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6211153	B1	20010403
APPLICATION INFO.:	US 1999-438718		19991111 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-108664, filed on 1 Jul 1998 Continuation of Ser. No. US 1995-573109, filed on 15 Dec 1995, now patented, Pat. No. US 5780435		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
LINE COUNT:	868		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex **steroid** biosynthesis to the subject in combination with the LHRH-R antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER:	2001:14465	USPATFULL
TITLE:	Methods for treating LHRH associated disorders with LHRH antagonists	
INVENTOR(S):	Garnick, Marc B., Brookline, MA, United States Molineaux, Christopher J., Brookline, MA, United States Gefter, Malcolm L., Lincoln, MA, United States	
PATENT ASSIGNEE(S):	Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180609	B1	20010130
APPLICATION INFO.:	US 1999-438174		19991111 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-108664, filed on 1 Jul 1998 Continuation of Ser. No. US 1995-573109, filed on 15 Dec 1995, now patented, Pat. No. US 5780435		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	814		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment

with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2000:160983 USPATFULL

TITLE: Methods for treating **prostate** cancer with LHRH-R antagonists

INVENTOR(S): Garnick, Marc B., Brookline, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States

PATENT ASSIGNEE(S): Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153586		20001128
APPLICATION INFO.:	US 1998-108664		19980701 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-573109, filed on 15 Dec 1995, now patented, Pat. No. US 5780435		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Laccotripe, Maria C.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	906		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 8 USPATFULL on STN

ACCESSION NUMBER: 1998:150905 USPATFULL

TITLE: Methods for treating **prostate** cancer with LHRH antagonists

INVENTOR(S): Garnick, Marc B., Brookline, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States

PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843902		19981201
APPLICATION INFO.:	US 1996-755593		19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-573109, filed on 15 Dec 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Lahive & Cockfield LLP, DeConti, Jr., Giulio A., Kara,
Catherine J.
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or radiation therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH agonist, either simultaneous with or subsequent to LHRH antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex **steroid** biosynthesis to the subject in combination with the LHRH antagonist. Methods for inhibiting the LHRH agonist-induced hormone surge, whatever its clinical setting, are also disclosed. These methods generally involve administration of an LHRH-antagonist in combination with the LHRH agonist. Complete suppression of the LHRH agonist-induced hormone surge has been achieved by pretreatment with a sustained-release formulation of LHRH antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 8 USPATFULL on STN

ACCESSION NUMBER: 1998:82723 USPATFULL
TITLE: Methods for treating **prostate** cancer with
LHRH-R antagonists
INVENTOR(S): Garnick, Marc B., Brookline, MA, United States
Molineaux, Christopher J., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780435		19980714
APPLICATION INFO.:	US 1995-573109		19951215 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Kara, Catherine J.		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1047		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating **prostate** cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys **prostatic** tumor tissue, such as a radical **prostatectomy**, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex **steroid** biosynthesis to the subject in combination with the LHRH-R antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1297840 EUROPATFULL EW 200314 FS OS
 TITLE: Methods for treating sex hormone-dependent conditions
 with LHRH antagonists.
 Behandlung von Sexualhormon-abhaengigen Zustaenden mit
 LHRH-Antagonisten.
 Traitement d'etats dependants de l'hormone sexuel avec
 des antagonistes de la luliberine.
 INVENTOR(S): Garnick, Marc B., 140 Dudley street, Brookline,
 Massachusetts 02146, US;
 Molineaux, Christopher J., 69 Center Street, Brookline,
 Massachusetts 02146, US;
 Gefter, Malcolm L., 46 Baker Bridge Road, Lincoln,
 Massachusetts 01773, US
 PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, One Hampshire
 Street, Cambridge, MA 02139-1572, US
 PATENT ASSIGNEE NO: 2205542
 AGENT: Holdcroft, James Gerald, Dr. et al., Graham Watt & Co.
 St. Botolph's House 7-9 St. Botolph's Road, Sevenoaks,
 Kent TN13 3AJ, GB
 AGENT NUMBER: 31911
 OTHER SOURCE: MEPA2003026 EP 1297840 A2 0021
 SOURCE: Wila-EPZ-2003-H14-T1b
 DOCUMENT TYPE: Patent
 LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
 DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
 GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
 PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG
 PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1297840	A2	20030402
'OFFENLEGUNGS' DATE: 20030402		
EP 2002-78871		19961125
PRIORITY APPLN. INFO.: US 1995-573109		19951215
RELATED DOC. INFO.: EP 871468	DIV	

=> d his

(FILE 'HOME' ENTERED AT 13:52:09 ON 17 SEP 2003)

FILE 'CAPLUS, USPATFULL, JAPIO, EUROPATFULL, MEDLINE, BIOSIS, EMBASE,
 CANCERLIT' ENTERED AT 13:52:58 ON 17 SEP 2003

L1 3581 S IMPLANT? AND BIODEGRAD? AND PROSTAT?
 L2 1105 S L1 AND STEROID?
 L3 105 S L2 AND PSA
 L4 57 S L3 AND (ESTROGEN? OR PROGESTER? OR CORTICOSTEROID?)
 L5 21 S L4 AND ((ANTI ANDROGEN?) OR FLUTAMIDE OR BICALUTAMIDE OR NIL
 L6 20 S L5 AND (MICROPART? OR MICROCAPSULE? OR MICROENCAPSUL? OR NAN
 L7 17 S L6 AND (SALINE OR ANESTHETIC OR ETHANOL)
 L8 8 S L7 AND (RETROPUBIC? OR (TRANSPERENNIAL?) OR (TRANSRECTAL?))
 L9 8 S L8 AND (SUBCUTANEOUS? OR INTRAMUSCULAR?)

=> s l5 and (lipd? or lipoid?) and carrier

L10 1 L5 AND (LIPD? OR LIPOID?) AND CARRIER

=> d l10 1 ibib abs

L10 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2003:213299 USPATFULL
TITLE: Prostatic hormonal implants
treatment of prostate cancer
INVENTOR(S): Sahadevan, Velayudhan, Beckley, WV, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147936	A1	20030807
APPLICATION INFO.:	US 2002-72416	A1	20020207 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Dr. V. Sahadevan, Dag Hammarskjold Cancer Treatment Center, 155 Dry Hill Road, Beckley, WV, 25801		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	4229		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk **prostate** cancers by **prostatic implants** of androgen suppressive drugs formulated as fused with a **lipoid carrier** or encapsulated in microcapsules or in Silastic capsules is provided. Such **prostatic implants** renders a constant slow-release of their contents to the **prostate** for extended periods by **biodegradation** and diffusion. It facilitates higher **prostatic** and lower systemic concentrations of androgen suppressive hormones. Because of their high **prostatic** and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal **implant** treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of **PSA** and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage **prostate** cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage **prostate** cancer significantly. Androgen suppressive hormonal **implants** to the **prostate** before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized **prostate** cancer as compared to the more complex and toxic higher dose radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 15 and silastic?
L11 3 L5 AND SILASTIC?

=> d l11 1-3 ibib abs

L11 ANSWER 1 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:226301 USPATFULL
TITLE: Anti-tumor agents
INVENTOR(S): Wallner, Barbara, Cohasset, MA, UNITED STATES
Miller, Glenn, Merrimac, MA, UNITED STATES
PATENT ASSIGNEE(S): Point Therapeutics, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158114	A1	20030821
APPLICATION INFO.:	US 2003-384121	A1	20030307 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-578363, filed on 25		

May 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-135861P	19990525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2082	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:213299 USPATFULL

TITLE: **Prostatic** hormonal **implants**
treatment of **prostate** cancer

INVENTOR(S): Sahadevan, Velayudhan, Beckley, WV, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147936	A1	20030807
APPLICATION INFO.:	US 2002-72416	A1	20020207 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Dr. V. Sahadevan, Dag Hammarskjold Cancer Treatment Center, 155 Dry Hill Road, Beckley, WV, 25801		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	4229		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk **prostate** cancers by **prostatic implants** of androgen suppressive drugs formulated as fused with a lipid carrier or encapsulated in microcapsules or in **Silastic** capsules is provided. Such **prostatic implants** renders a constant slow-release of their contents to the **prostate** for extended periods by **biodegradation** and diffusion. It facilitates higher **prostatic** and lower systemic concentrations of androgen suppressive hormones. Because of their high **prostatic** and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal **implant** treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of **PSA** and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage **prostate** cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage **prostate** cancer significantly. Androgen suppressive hormonal **implants** to the **prostate** before, during or after lower dose

conventional radiation therapy would also facilitate equal or better cure rates of localized **prostate** cancer as compared to the more complex and toxic higher dose radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2003:153332 USPATFULL
TITLE: Methods and compositions for inhibiting GRB7
INVENTOR(S): Pero, Stephanie C., Essex Junction, VT, UNITED STATES
Krag, David N., Shelburne, VT, UNITED STATES
Oligino, Lyn, South Burlington, VT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105000	A1	20030605
APPLICATION INFO.:	US 2001-13815	A1	20011105 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245755P	20001103 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	93	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	4785	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods and compositions for treating subjects using Grb7 antagonists. Specifically disclosed are Grb7 antagonists that bind selectively to Grb7 and interfere with the ability of Grb7 to bind to its native ligands. These compositions are useful in the prevention and treatment of disorders characterized by abnormal interaction of Grb7 with its native ligands (e.g., ErbB2).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s prostat? and implant?
L12 17364 PROSTAT? AND IMPLANT?

=> s l12 and (drug delivery)
L13 3835 L12 AND (DRUG DELIVERY)

=> s l13 and steroid?
L14 1258 L13 AND STEROID?

=> s l14 and (estrogen? or progester? or cortisone?)
L15 770 L14 AND (ESTROGEN? OR PROGESTER? OR CORTISONE?)

=> s l15 and antiandrogen?
L16 194 L15 AND ANTIANDROGEN?

=> s l16 and (flutamide or bicalutamide or nilutamide or estramustine)
L17 174 L16 AND (FLUTAMIDE OR BICALUTAMIDE OR NILUTAMIDE OR ESTRAMUSTIN
E)

=> s l17 and (hormonal treatment?)
L18 6 L17 AND (HORMONAL TREATMENT?)

=> d l18 1-6 ibib abs

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:609870 CAPLUS
DOCUMENT NUMBER: 139:112170
TITLE: **Prostatic hormonal implants for
the treatment of prostate cancer**
INVENTOR(S): Sahadevan, Velayudhan
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147936	A1	20030807	US 2002-72416	20020207
US 2003149008	A1	20030807	US 2002-85840	20020227

PRIORITY APPLN. INFO.: US 2002-72416 A2 20020207

AB An improved method and products for the primary **hormonal treatment** of early stage, low and intermediate risk **prostate** cancers by **prostatic implants** of androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such **prostatic implants** renders a const. slow-release of their contents to the **prostate** for extended periods by biodegrdn. and diffusion. It facilitates higher **prostatic** and lower systemic concns. of androgen suppressive hormones. Because of their high **prostatic** and lower systemic concns., tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal **implant** treatment is followed by clin. examns. and the biochem. tumor control is followed by periodic estns. of serum levels of PSA and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage **prostate** cancer is reserved for those patients failing to this primary **hormonal treatment**. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage **prostate**

cancer significantly. Androgen suppressive hormonal **implants** to the **prostate** before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized **prostate** cancer as compared to the more complex and toxic higher dose radiation therapy.

L18 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:213299 USPATFULL

TITLE: **Prostatic** hormonal **implants**
treatment of **prostate** cancer

INVENTOR(S): Sahadevan, Velayudhan, Beckley, WV, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003147936	A1	20030807
APPLICATION INFO.:	US 2002-72416	A1	20020207 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Dr. V. Sahadevan, Dag Hammarskjold Cancer Treatment Center, 155 Dry Hill Road, Beckley, WV, 25801		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	4229		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved method and products for the primary **hormonal treatment** of early stage, low and intermediate risk **prostate** cancers by **prostatic implants** of androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such **prostatic implants** renders a constant slow-release of their contents to the **prostate** for extended periods by biodegradation and diffusion. It facilitates higher **prostatic** and lower systemic concentrations of androgen suppressive hormones. Because of their high **prostatic** and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal **implant** treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of PSA and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage **prostate** cancer is reserved for those patients failing to this primary **hormonal treatment**. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage **prostate** cancer significantly. Androgen suppressive hormonal **implants** to the **prostate** before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized **prostate** cancer as compared to the more complex and toxic higher dose radiation therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:93647 USPATFULL

TITLE: Selective **estrogen** receptor modulators in combination with **estrogens**

INVENTOR(S): Labrie, Fernand, Sainte-foy, CANADA

PATENT ASSIGNEE(S): Endorecherche, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065008	A1	20030403
APPLICATION INFO.:	US 2002-143894	A1	20020509 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-771180, filed on 26
Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178601P	20000128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	3036	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective **estrogen** receptor modulator, particularly compounds having the general structure
##STR1##

and an amount of an **estrogen** or mixed **estrogenic** /androgenic compound. Further administration of bisphosphonates, or sex **steroid** precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2003:57944	USPATFULL
TITLE:	Selective estrogen receptor modulators in combination with estrogens	
INVENTOR(S):	Labrie, Fernand, Sainte-foy, CANADA	
PATENT ASSIGNEE(S):	Endorecherche, Inc. (non-U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040510	A1	20030227
APPLICATION INFO.:	US 2001-52824	A1	20011107 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-771180, filed on 26 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178601P	20000128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	2854	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast

or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective **estrogen** receptor modulator, particularly compounds having the general structure:
##STR1##

and an amount of an **estrogen** or mixed **estrogenic** /androgenic compound. Further administration of bisphosphonates, or sex **steroid** precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:344449 USPATFULL
TITLE: Selective **estrogen** receptor modulators in combination with **estrogens**
INVENTOR(S): Labrie, Fernand, Sainte-foy, CANADA
PATENT ASSIGNEE(S): Endorecherche, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198179	A1	20021226
APPLICATION INFO.:	US 2001-52803	A1	20011107 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-771180, filed on 26 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178601P	20000128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM.:	1	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	3044	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective **estrogen** receptor modulator, particularly compounds having the general structure:
##STR1##

and an amount of an **estrogen** or mixed **estrogenic** /androgenic compound. Further administration of bisphosphonates, or sex **steroid** precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:92084 USPATFULL

TITLE: Suppository and composition comprising at least one polyethylene glycol

INVENTOR(S): Beckett, Christian Westy, Aalsgaarde, DENMARK
Eliassen, Per Robert Topp, Korsoer, DENMARK

PATENT ASSIGNEE(S): Anestic ApS, Aalsgaarde, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048601	A1	20020425
APPLICATION INFO.:	US 2001-899567	A1	20010706 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-1067	20000707
	DK 2000-1923	20001221
	DK 2001-1050	20010703
	US 2000-256923P	20001221 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW,
SUITE 300, WASHINGTON, DC, 20001-5303

NUMBER OF CLAIMS: 90

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 10 Drawing Page(s)

LINE COUNT: 2819

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a suppository comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable, and wherein the suppository essentially does not swell when contacted with an aqueous fluid. The suppository may further comprise a plurality of open cells at least partly separated from one another by an interpenetrating matrix comprising at least one biocompatible polymer in branched or crosslinked form. The plurality of interlinked, open cells are capable of containing an aqueous fluid, and the permeability of the suppository ensures that entry of body fluids into the open cells under practical circumstances occurs essentially without dehydration of mucousal membrane tissue contacting the suppository. The suppository furthermore preferably comprises a controlled release formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right